Dyne and PepGen Surge as Likely Winners from Novartis/Avidity Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 27 2025
0mins
Should l Buy PEPG?
Source: SeekingAlpha
Market Reaction: Dyne Therapeutics and PepGen saw significant stock increases of approximately 41% and 21%, respectively, following Novartis' $12 billion acquisition of Avidity Biosciences.
Avidity's Developments: Avidity is advancing treatments for rare muscular dystrophies, including Del-zota for Duchenne muscular dystrophy and other candidates for myotonic dystrophy type 1 and facioscapulohumeral muscular dystrophy.
Dyne's Pipeline: Dyne Therapeutics is working on two candidates for myotonic dystrophy type 1, utilizing its proprietary FORCE platform, with data expected by mid-2026.
PepGen's Trials: PepGen is developing PGN-EDODM1 for myotonic dystrophy type 1 and is currently recruiting for two clinical trials, one in phase 1 and another in phase 2.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PEPG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PEPG
Wall Street analysts forecast PEPG stock price to rise
2 Analyst Rating
1 Buy
0 Hold
1 Sell
Hold
Current: 5.570
Low
3.00
Averages
11.50
High
20.00
Current: 5.570
Low
3.00
Averages
11.50
High
20.00
About PEPG
PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PepGen Faces FDA Clinical Hold Investigation
- FDA Clinical Hold: On March 5, 2026, PepGen disclosed that the FDA imposed a partial clinical hold on its PGN-EDODM1 FREEDOM2-DM1 trial due to concerns regarding previously submitted pharmacology and toxicology studies, which could significantly impact the company's research and development trajectory and market confidence.
- Sharp Stock Decline: Following the FDA announcement, PepGen's stock price plummeted during intraday trading on March 5, 2026, indicating investor anxiety over regulatory developments and uncertainty surrounding the FREEDOM2 clinical program, potentially leading to decreased investor confidence and capital outflows.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether PepGen and its executives violated federal securities laws, and investors who suffered losses from PepGen stock are encouraged to join the investigation, which may affect the company's legal liabilities and future financial performance.
- Investor Rights Protection: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm, ranked among the Top 10 Plaintiff Law Firms in 2024, reflecting its effectiveness in advocating for investors, which may attract more affected investors seeking legal recourse.
See More
PepGen Shares Drop After FDA Partially Halts Clinical Trial
- FDA Clinical Hold: PepGen's PGN-EDODM1 trial targeting myotonic dystrophy type 1 faces a partial clinical hold from the FDA due to concerns over submitted pharmacology and toxicology studies, potentially impacting the company's future R&D efforts.
- Trial Phase Impact: The hold affects the FREEDOM2-DM1 Phase 2 trial, and while the Phase 1 FREEDOM study data remains unchallenged, this decision may lead to delays in clinical progress, thereby affecting investor confidence.
- Data Submission Commitment: PepGen has committed to submitting additional analyses to the FDA, including recently unblinded FREEDOM data, indicating the company's dedication to addressing FDA inquiries swiftly to restore trial progress and maintain market position.
- Market Reaction: Following the FDA's announcement of the partial hold, PepGen shares continued to decline in premarket trading, reflecting market unease regarding the company's clinical trial outlook, which could negatively impact its financing and future growth.
See More
Veeva Systems Reports Strong Q4 Results and Raises FY27 Guidance
- Strong Financials: Veeva Systems reported Q4 revenue of $836 million, a 16% year-over-year increase, surpassing the market expectation of $810.6 million, indicating robust growth potential in the life sciences sector.
- Earnings Beat: The company posted earnings per share of $2.06, exceeding the consensus estimate of $1.93, reflecting ongoing improvements in profitability and boosting investor confidence.
- Stock Surge: Veeva Systems shares jumped 11.3% in pre-market trading to $209.81, indicating a positive market reaction to its financial performance and future outlook.
- Optimistic Guidance: The company raised its FY27 guidance above market expectations, further solidifying its leadership position in the industry and laying a strong foundation for future growth.
See More
PepGen Reports Q4 2025 Earnings Beat with Strong Cash Position
- Earnings Beat: PepGen's Q4 2025 report reveals a GAAP EPS of -$0.27, surpassing expectations by $0.12, indicating improvements in financial management and operational efficiency.
- Strong Cash Reserves: As of December 31, 2025, the company holds $148.5 million in cash, cash equivalents, and marketable securities, ensuring operational stability for the coming years.
- Funding Outlook: Based on current operational plans, PepGen believes its existing cash and equivalents will sufficiently fund operations into the second half of 2027, reflecting a solid financial position.
- Increased Market Attention: The earnings report has heightened market interest in PepGen, boosting investor confidence in its growth potential, which may positively influence the stock price.
See More
PepGen Faces FDA Partial Hold on FREEDOM2 Trial Amid Regulatory Concerns
- FDA Partial Hold: The U.S. FDA has placed PepGen's FREEDOM2-DM1 trial on a partial clinical hold due to concerns regarding preclinical pharmacology and toxicology studies, which may hinder the company's future clinical progress and investor confidence.
- Shift in Research Focus: In May 2025, PepGen voluntarily discontinued the development of PGN-EDO51, redirecting its efforts towards myotonic dystrophy type 1 (DM1), a strategic shift that could impact its market positioning and allocation of R&D resources.
- International Trial Approval: Despite facing challenges from the FDA, PepGen has received regulatory clearance to initiate the FREEDOM2 study in South Korea, Australia, and New Zealand, indicating potential for expansion in global markets.
- Declining Stock Performance: PepGen shares fell 14.20% during premarket trading to $5.80, significantly below its 20-day and 100-day simple moving averages, reflecting a bearish outlook from the market regarding its future developments.
See More
PepGen Appoints New Chief Business Officer with 160,000 Stock Options Grant
- Executive Appointment: PepGen Inc. appointed Joseph Vittiglio as Chief Business and Legal Officer, granting him 160,000 non-qualified stock options under the 2024 Inducement Plan, with an exercise price of $5.59 per share, reflecting the company's commitment to strengthening its executive team.
- Stock Option Structure: The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the one-year anniversary of Vittiglio's employment and the remainder vesting in equal monthly installments, aimed at incentivizing his long-term service to the company.
- Plan Background: This grant is made under PepGen's 2024 Inducement Plan, adopted by the Board in August 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), indicating the company's strategic intent to attract top talent.
- Company Vision: PepGen is focused on advancing next-generation oligonucleotide therapies to transform the treatment of severe neuromuscular and neurological diseases, and Vittiglio's addition is expected to contribute significantly to achieving this vision.
See More
PepGen Faces FDA Clinical Hold Investigation
- FDA Clinical Hold: On March 5, 2026, PepGen disclosed that the FDA imposed a partial clinical hold on its PGN-EDODM1 FREEDOM2-DM1 trial due to concerns regarding previously submitted pharmacology and toxicology studies, which could significantly impact the company's research and development trajectory and market confidence.
- Sharp Stock Decline: Following the FDA announcement, PepGen's stock price plummeted during intraday trading on March 5, 2026, indicating investor anxiety over regulatory developments and uncertainty surrounding the FREEDOM2 clinical program, potentially leading to decreased investor confidence and capital outflows.
- Legal Investigation Initiated: Johnson Fistel, PLLP is investigating whether PepGen and its executives violated federal securities laws, and investors who suffered losses from PepGen stock are encouraged to join the investigation, which may affect the company's legal liabilities and future financial performance.
- Investor Rights Protection: Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm, ranked among the Top 10 Plaintiff Law Firms in 2024, reflecting its effectiveness in advocating for investors, which may attract more affected investors seeking legal recourse.
See More
PepGen Shares Drop After FDA Partially Halts Clinical Trial
- FDA Clinical Hold: PepGen's PGN-EDODM1 trial targeting myotonic dystrophy type 1 faces a partial clinical hold from the FDA due to concerns over submitted pharmacology and toxicology studies, potentially impacting the company's future R&D efforts.
- Trial Phase Impact: The hold affects the FREEDOM2-DM1 Phase 2 trial, and while the Phase 1 FREEDOM study data remains unchallenged, this decision may lead to delays in clinical progress, thereby affecting investor confidence.
- Data Submission Commitment: PepGen has committed to submitting additional analyses to the FDA, including recently unblinded FREEDOM data, indicating the company's dedication to addressing FDA inquiries swiftly to restore trial progress and maintain market position.
- Market Reaction: Following the FDA's announcement of the partial hold, PepGen shares continued to decline in premarket trading, reflecting market unease regarding the company's clinical trial outlook, which could negatively impact its financing and future growth.
See More
Veeva Systems Reports Strong Q4 Results and Raises FY27 Guidance
- Strong Financials: Veeva Systems reported Q4 revenue of $836 million, a 16% year-over-year increase, surpassing the market expectation of $810.6 million, indicating robust growth potential in the life sciences sector.
- Earnings Beat: The company posted earnings per share of $2.06, exceeding the consensus estimate of $1.93, reflecting ongoing improvements in profitability and boosting investor confidence.
- Stock Surge: Veeva Systems shares jumped 11.3% in pre-market trading to $209.81, indicating a positive market reaction to its financial performance and future outlook.
- Optimistic Guidance: The company raised its FY27 guidance above market expectations, further solidifying its leadership position in the industry and laying a strong foundation for future growth.
See More
PepGen Reports Q4 2025 Earnings Beat with Strong Cash Position
- Earnings Beat: PepGen's Q4 2025 report reveals a GAAP EPS of -$0.27, surpassing expectations by $0.12, indicating improvements in financial management and operational efficiency.
- Strong Cash Reserves: As of December 31, 2025, the company holds $148.5 million in cash, cash equivalents, and marketable securities, ensuring operational stability for the coming years.
- Funding Outlook: Based on current operational plans, PepGen believes its existing cash and equivalents will sufficiently fund operations into the second half of 2027, reflecting a solid financial position.
- Increased Market Attention: The earnings report has heightened market interest in PepGen, boosting investor confidence in its growth potential, which may positively influence the stock price.
See More
PepGen Faces FDA Partial Hold on FREEDOM2 Trial Amid Regulatory Concerns
- FDA Partial Hold: The U.S. FDA has placed PepGen's FREEDOM2-DM1 trial on a partial clinical hold due to concerns regarding preclinical pharmacology and toxicology studies, which may hinder the company's future clinical progress and investor confidence.
- Shift in Research Focus: In May 2025, PepGen voluntarily discontinued the development of PGN-EDO51, redirecting its efforts towards myotonic dystrophy type 1 (DM1), a strategic shift that could impact its market positioning and allocation of R&D resources.
- International Trial Approval: Despite facing challenges from the FDA, PepGen has received regulatory clearance to initiate the FREEDOM2 study in South Korea, Australia, and New Zealand, indicating potential for expansion in global markets.
- Declining Stock Performance: PepGen shares fell 14.20% during premarket trading to $5.80, significantly below its 20-day and 100-day simple moving averages, reflecting a bearish outlook from the market regarding its future developments.
See More
PepGen Appoints New Chief Business Officer with 160,000 Stock Options Grant
- Executive Appointment: PepGen Inc. appointed Joseph Vittiglio as Chief Business and Legal Officer, granting him 160,000 non-qualified stock options under the 2024 Inducement Plan, with an exercise price of $5.59 per share, reflecting the company's commitment to strengthening its executive team.
- Stock Option Structure: The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the one-year anniversary of Vittiglio's employment and the remainder vesting in equal monthly installments, aimed at incentivizing his long-term service to the company.
- Plan Background: This grant is made under PepGen's 2024 Inducement Plan, adopted by the Board in August 2024, in accordance with Nasdaq Listing Rule 5635(c)(4), indicating the company's strategic intent to attract top talent.
- Company Vision: PepGen is focused on advancing next-generation oligonucleotide therapies to transform the treatment of severe neuromuscular and neurological diseases, and Vittiglio's addition is expected to contribute significantly to achieving this vision.
See More
